Product Description
Fomivirsen (ISIS 2922) is an antisense oligonucleotide which specifically inhibits replication of human cytomegalovirus. It achieves this by binding to complementary sequences on messenger RNA transcribed from the major immediate-early transcriptional unit of the virus. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10193689/)
Mechanisms of Action: DNA Replication Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Brazil | European Medicines Agency | Germany | Ireland | Italy | Portugal
Approved Indications: None
Known Adverse Events: None
Company: Ionis
Company Location: CARLSBAD CA 92010
Company CEO: Brett P. Monia
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cytomegalovirus Infections|HIV Infections|Acquired Immunodeficiency Syndrome|Cytomegalovirus Retinitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 251D | N/A |
Completed |
Cytomegalovirus Retinitis|HIV Infections|Cytomegalovirus Infections |
None |
2019-03-21 |
Treatments |
|
| 251C | P2 |
Completed |
Cytomegalovirus Infections|HIV Infections|Acquired Immunodeficiency Syndrome|Cytomegalovirus Retinitis |
None |
2019-03-21 |
Treatments |
|
| 251A | N/A |
Completed |
Cytomegalovirus Retinitis|Cytomegalovirus Infections|HIV Infections |
None |
2019-03-21 |
Treatments |